Guggenheim analyst Vamil Divan raised the firm’s price target on AbbVie (ABBV) to $216 from $214 and keeps a Buy rating on the shares. AbbVie reported “an impressive quarter,” with results beating expectations on both sales and quarterly EPS, notes the analyst, who is updating the firm’s model following the company’s Q1 earnings results last week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- AbbVie price target raised to $227 from $220 at Raymond James
- AbbVie price target raised to $204 from $200 at BofA
- AbbVie price target lowered to $205 from $230 at HSBC
- AbbVie: Strong Financial Performance and Growth Prospects Drive Positive Analyst Outlook
- AbbVie price target raised to $250 from $241 at Morgan Stanley